HCPLive Network

FDA Approves Ravicti for Urea Cycle Disorders

Primary Care   |   Hospital Medicine   |   Pediatrics   |   Nephrology   |  
 
FDA Approves Ravicti for Urea Cycle DisordersFRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia build-up can lead to coma, brain damage, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence, and headache.

Ravicti is marketed by Hyperion Therapeutics, based in San Francisco.
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
High-dose ascorbic acid supplements are associated with a significantly increased risk of kidney stone formation in men, according to a research letter published online Feb. 4 in JAMA Internal Medicine.
Synthetic cannabinoids, sold under labels such as "synthetic marijuana," "herbal incense," "potpourri," and "spice" have been tied to hospitalizations for unexplained acute kidney injury in the United States, according to research published in the Feb. 15 issue of the U.S. Centers for Disease Control and Prevention's Morbidity & Mortality Weekly Report.
Nonsteroidal anti-inflammatory drug-associated acute kidney injury (AKI) accounts for almost 3 percent of pediatric AKI, according to a study published online Jan. 28 in The Journal of Pediatrics.
$AD300x250BB$